Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Sells $615,024.60 in Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver sold 50,002 shares of the company’s stock in a transaction dated Monday, April 7th. The stock was sold at an average price of $12.30, for a total transaction of $615,024.60. Following the completion of the sale, the director now directly owns 210,346 shares of the company’s stock, valued at $2,587,255.80. The trade was a 19.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Laura Shawver also recently made the following trade(s):

• On Thursday, March 6th, Laura Shawver sold 49,600 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $11.21, for a total value of $556,016.00.
• On Monday, February 3rd, Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $12.31, for a total value of $615,500.00.

ARS Pharmaceuticals Stock Down 0.7 %

NASDAQ SPRY opened at $13.24 on Friday. The company has a market cap of $1.30 billion, a PE ratio of -25.96 and a beta of 0.86. The firm’s 50-day simple moving average is $11.97 and its two-hundred day simple moving average is $13.04. ARS Pharmaceuticals, Inc. has a 52 week low of $7.55 and a 52 week high of $18.51.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its quarterly earnings data on Thursday, March 20th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.56. The business had revenue of $86.58 million during the quarter, compared to the consensus estimate of $15.46 million. As a group, equities research analysts anticipate that ARS Pharmaceuticals, Inc. will post -0.55 EPS for the current year.

Hedge Funds Weigh In On ARS Pharmaceuticals

Several hedge funds have recently made changes to their positions in the stock. Bernard Wealth Management Corp. purchased a new stake in ARS Pharmaceuticals during the 4th quarter worth about $27,000. KLP Kapitalforvaltning AS bought a new stake in shares of ARS Pharmaceuticals during the fourth quarter valued at about $73,000. BNP Paribas Financial Markets purchased a new stake in shares of ARS Pharmaceuticals in the fourth quarter worth about $75,000. Ball & Co Wealth Management Inc. purchased a new position in ARS Pharmaceuticals during the fourth quarter valued at approximately $105,000. Finally, Compass Capital Corp MA ADV bought a new stake in ARS Pharmaceuticals during the 4th quarter worth approximately $106,000. 68.16% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on SPRY. Oppenheimer started coverage on ARS Pharmaceuticals in a research report on Monday, February 10th. They set an “outperform” rating and a $40.00 target price for the company. Scotiabank started coverage on shares of ARS Pharmaceuticals in a report on Friday, March 7th. They set a “sector outperform” rating and a $30.00 price objective for the company. William Blair reiterated an “outperform” rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Raymond James raised their price target on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a research note on Tuesday, January 14th. Finally, Leerink Partners lifted their price target on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $31.00.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.